On April 19, 2023, the Company entered into an asset purchase agreement to sell substantially all of the assets related to ENTADFI® (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia that was approved by the FDA in December 2021, with Blue Water Vaccines Inc. (“BWV”). The transaction closed on April 19, 2023. The purchase price for the transaction was $20.0 million, consisting of $6.0 million paid at closing, $4.0 million payable by September 30, 2023, $5.0 million payable 12 months after closing, and $5.0 million payable by September 30, 2024, plus up to $80.0 million based on BWV’s net revenues from ENTADFI after closing (the “Milestone Payments”). The Company cannot determine the likelihood of receiving any Milestone Payments at this time. The Company determined the gain on sale of ENTADFI based on the purchase price of $20.0 million, net of imputed interest on the interest-free notes receivable, using an interest rate of 10%, of $1.3 million. Total assets sold, consisting primarily of inventory, had a net book value of approximately $1.3 million. The Company recorded a gain of approximately $17.5 million on the transaction and recognized imputed interest income of $241,000 during the three months ended June 30, 2023. As of June 30, 2023, the net short-term and long-term notes receivable balances are $8.5 million and $4.4 million, respectively, and are presented as separate line items on the accompanying unaudited condensed consolidated balance sheet as of June 30, 2023.